

EQA round: RF1/24 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 15.3.2024

Setup: groups - M (measurement principle)

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(277) anti-CCP IgG		80			80	80	100	
Sample A1		80			80	80	100	
(2) EIA (ELISA)	CVP >>>	32	40	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	4	5	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	44	55	Negative				
Sample B1		80			80	80	100	
(2) EIA (ELISA)	CVP >>>	32	40	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	4	5	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	44	55	Positive				
(282) anti-MCV		24			24	24	100	
Sample A1		24			24	24	100	
(2) EIA (ELISA)	CVP >>>	23	96	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	1	4,2	Negative				
Sample B1		24			24	24	100	
(2) EIA (ELISA)	CVP >>>	23	96	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	1	4,2	Positive				
(231) Rheumat. fac. (scr)		174			174	174	100	
Sample A1		174			174	174	100	
(2) EIA (ELISA)	CVP >>>	2	1,1	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	0,6	Negative				
(6) IMT, IMN	CVP >>>	170	98	Negative				
(7) Semi-quant. aglut. m.	CVP >>>	1	0,6	Negative				
Sample B1		174			174	174	100	
(2) EIA (ELISA)	CVP >>>	2	1,1	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	0,6	Positive				
(6) IMT, IMN	CVP >>>	170	98	Positive				
(7) Semi-quant. aglut. m.	CVP >>>	1	0,6	Positive				
(234) Rheumat. factor IgA		43			43	43	100	
Sample A1		43			43	43	100	
(0) Not specified	CVP >>>	7	16	Negative				
(2) EIA (ELISA)	CVP >>>	32	74	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	3	7	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Negative				
Sample B1		43			43	43	100	
(0) Not specified	CVP >>>	7	16	Positive				
(2) EIA (ELISA)	CVP >>>	32	74	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	3	7	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Positive				
(233) Rheumat. factor IgG		44			44	43	98	
Sample A1		44			44	44	100	
(0) Not specified	CVP >>>	7	16	Negative				
(2) EIA (ELISA)	CVP >>>	32	73	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	2	4,5	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Negative				
(6) IMT, IMN	CVP >>>	2	4,5	Negative				
Sample B1		44			44	43	98	
(0) Not specified	CVP >>>	7	16	Positive				
(2) EIA (ELISA)	CVP >>>	1	2,3	Negative				
	CVP >>>	31	70	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	2	4,5	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Positive				
(6) IMT, IMN	CVP >>>	2	4,5	Positive				
(235) Rheumat. factor IgM		44			44	44	100	
Sample A1		44			44	44	100	
(0) Not specified	CVP >>>	7	16	Negative				
(2) EIA (ELISA)	CVP >>>	32	73	Negative				
(3) FIA (FEIA, TRACE)	CVP >>>	3	6,8	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Negative				
(6) IMT, IMN	CVP >>>	1	2,3	Negative				
Sample B1		44			44	44	100	
(0) Not specified	CVP >>>	7	16	Positive				
(2) EIA (ELISA)	CVP >>>	32	73	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	3	6,8	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	2,3	Positive				

EQA round: RF1/24 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 15.3.2024

Setup: groups - M (measurement principle)

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(6) IMT, IMN	CVP >>>	1	2,3	Positive			